Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 8, Issue 11, Pages 1743-1749Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.11.1743
Keywords
combination therapy; hepatocellular carcinoma; sorafenib; targeted therapy; transcatheter arterial chemoembolization
Categories
Ask authors/readers for more resources
Depending on tumor burden, hepatic function and patients' performance status, hepatocellular carcinoma is treated by surgery, local procedures, systemic therapy or palliation. The majority of patients are diagnosed at a stage where local therapy is the treatment of choice. Recently, the multikinase inhibitor sorafenib was found to improve the survival of patients with advanced hepatocellular carcinoma and conserved liver function. In this manuscript, we summarize the experimental evidence supporting the combination of a systemic targeted therapy with a local therapy. We also discuss the pros and cons of different schedules of combining such treatments. We conclude that there is enough of a theoretical argument to design clinical trials testing this strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available